explore -WSS

explore

author：knowledge 2025-10-03 19:57:14 - browse：14

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Life science postdocs should get big pay hike, NIH panel says

WSS

Arena BioWorks launches in Cambridge to speed drug discovery

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Patients' immediate access to test results puts radiologists in a bind

Leukemia patients are helped by Syndax's new type of therapy

FDA needs staff influx to meet gene therapy needs, Marks says

FDA early review: GLP

leisure time

explore

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Ascension's ugly legal battle over care for poor patients in Texas

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Roche to buy Carmot Therapeutics, developer of obesity drugs

Anesthesiologist group: stop taking Ozempic before surgery

Medicare Advantage overpayments discussion gets experts fired up

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT letters to the editor on burnt

Continuity nursing helped my family in our darkest PICU moments

Stories you might have missed in 2023: health, science, medicine

Wikipedia

Hospital chaplains balance Covid safety with patients’ spiritual needs

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

FDA needs staff influx to meet gene therapy needs, Marks says

Why sickle cell disease is getting the first CRISPR treatment

Hospital chaplains balance Covid safety with patients’ spiritual needs

Study suggests new cause of Down syndrome: cells linked to aging

Wikipedia

leisure time

entertainment

explore